Oncology & Cancer

Molecular mechanisms behind AICAr drug; impact on ALL

AICAr (5-amino-4-imidazolecarboxamide riboside, also called Acadesine) has been found to inhibit cell proliferation and has cytotoxic potential for childhood acute lymphoblastic leukemia (ALL) cells. Much of the drug's cytotoxic ...

Oncology & Cancer

Tailoring treatment in ovarian cancer

(Medical Xpress)—The prognosis for ovarian cancer patients is poor with only 3 out of 10 women living at least 5 years after diagnosis. Clinicians urgently need the tools to provide a more accurate prognosis for patients ...

Medical research

Researchers discover a new player in tumor suppression and aging

A study conducted by the Spanish National Cancer Research Centre´s (CNIO) Genomic Instability Group, led by Óscar Fernández-Capetillo, describes for the first time in mammals, the role played by the SMC5/6 protein complex ...

Oncology & Cancer

Individual efficacy of chemotherapies

The function of the mitochondria – also defined as "power plants" within the cells – is essential as to whether, and how, some chemotherapeutic agents take effect in tissue. Scientists at the Helmholtz Zentrum München ...

Oncology & Cancer

New research may aid treatment of multiple myeloma patients

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which ...

Oncology & Cancer

AACR: tumor vulnerability varies with clonal evolution in ALL

(HealthDay)—In acute lymphoblastic leukemia (ALL), tumor vulnerability to different chemotherapeutic agents varies at different stages of clonal evolution, which could represent a viable strategy in avoiding drug resistance. ...

page 3 from 6